Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection

Ammirati, Enrico; Cavalotti, Cristina; Milazzo, Angela; Pedrotti, Patrizia; Soriano, Francesco; Schroeder, Jan Walter; Morici, Nuccia; Giannattasio, Cristina; Frigerio, Maria; Metra, Marco; Camici, Paolo G.; Oliva, Fabrizio

doi:10.1016/j.ijcha.2021.100774

Cited by 75 publications

(97 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a conclusive causal link to vaccination has not been confirmed at this time. Additionally, two recently published European case reports describe myocarditis after COVID-19 mRNA vaccination in a 56-year-old man with previous COVID-19 and a 39-year-old man with no history of COVID-19 6,7 . This report summarizes case histories of 7 healthy male adolescents 14 to 19 years of age who developed acute myocarditis or myopericarditis within 4 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, none of whom met criteria for MIS-C. All 7 patients were vaccinated in April and May of 2021 and have been reported to VAERS.…”

Section: Introductionmentioning

confidence: 99%

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

et al. 2021

View full text Add to dashboard Cite

This is a prepublication version of an article that has undergone peer review and been accepted for publication but is not the final version of record. This paper may be cited using the DOI and date of access. This paper may contain information that has errors in facts, figures, and statements, and will be corrected in the final published version. The journal is providing an early version of this article to expedite access to this information. The American Academy of Pediatrics, the editors, and authors are not responsible for inaccurate information and data described in this version.

show abstract

Section: Introductionmentioning

confidence: 99%

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Conversely, in the current era of heightened surveillance by the CDC's vaccine safety data (VSD) working group and the Vaccine Related Biological Products Advisory Committee (VRBPAC) on immunization practices after COVID-19, and postmarketing surveillance by the vaccine producing companies in the setting of conditional marketing authorization, the reporting of probable myocarditis and pericarditis cases is significantly higher. Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination, particularly in adolescents and young adults [7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?

et al. 2021

View full text Add to dashboard Cite

This is a cross-sectional study of 29 published cases of acute myopericarditis following COVID-19 mRNA vaccination. The most common presentation was chest pain within 1–5 days after the second dose of mRNA COVID-19 vaccination. All patients had an elevated troponin. Cardiac magnetic resonance imaging revealed late gadolinium enhancement consistent with myocarditis in 69% of cases. All patients recovered clinically rapidly within 1–3 weeks. Most patients were treated with non-steroidal anti-inflammatory drugs for symptomatic relief, and 4 received intravenous immune globulin and corticosteroids. We speculate a possible causal relationship between vaccine administration and myocarditis. The data from our analysis confirms that all myocarditis and pericarditis cases are mild and resolve within a few days to few weeks. The bottom line is that the risk of cardiac complications among children and adults due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection far exceeds the minimal and rare risks of vaccination-related transient myocardial or pericardial inflammation.

show abstract

“…Two case reports have been published in the medical literature about myocarditis post BNT162b2 vaccination [ 7 , 8 ]. Like our case, Ammirati et al reported a male patient who had myocarditis 72 h after the second dose of BNT162b2 vaccine with favorable hospital course (8).…”

Section: Discussionmentioning

confidence: 99%

Acute myocarditis following administration of BNT162b2 vaccine

Habib

Hamamyh

Elyas

et al. 2021

IDCases

View full text Add to dashboard Cite

show abstract

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection

Cited by 75 publications

References 15 publications

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?

Acute myocarditis following administration of BNT162b2 vaccine

Contact Info

Product

Resources

About